AA Pipeline Update: Equillium’s EQ101 Shows Promise in Phase 2 Trial
Equillium, Inc.’s EQ101 performed well in adults with moderate, severe or very-severe alopecia areata (AA), according to topline data from a Phase 2, single dose, proof-of-concept study. EQ101 is a novel multi-cytokine inhibitor with a targeted mechanism of action against interleukin (IL)-2, IL-9 and IL-15, which are key drivers of the pathogenic T cells implicated […]